PL2931313T3 - Preparaty roztworów modyfikowanych przeciwciał anty-il-23p19 - Google Patents
Preparaty roztworów modyfikowanych przeciwciał anty-il-23p19Info
- Publication number
- PL2931313T3 PL2931313T3 PL13863590T PL13863590T PL2931313T3 PL 2931313 T3 PL2931313 T3 PL 2931313T3 PL 13863590 T PL13863590 T PL 13863590T PL 13863590 T PL13863590 T PL 13863590T PL 2931313 T3 PL2931313 T3 PL 2931313T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- solution formulations
- engineered anti
- engineered
- formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737035P | 2012-12-13 | 2012-12-13 | |
| PCT/US2013/073825 WO2014093203A1 (en) | 2012-12-13 | 2013-12-09 | SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES |
| EP13863590.9A EP2931313B1 (en) | 2012-12-13 | 2013-12-09 | Solution formulations of engineered anti-il-23p19 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2931313T3 true PL2931313T3 (pl) | 2019-10-31 |
Family
ID=50934859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13863590T PL2931313T3 (pl) | 2012-12-13 | 2013-12-09 | Preparaty roztworów modyfikowanych przeciwciał anty-il-23p19 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20150329632A1 (pl) |
| EP (1) | EP2931313B1 (pl) |
| JP (1) | JP6266012B2 (pl) |
| KR (1) | KR102004585B1 (pl) |
| CN (1) | CN104870016B (pl) |
| AU (1) | AU2013359767B2 (pl) |
| BR (1) | BR112015013540B1 (pl) |
| CA (1) | CA2894869C (pl) |
| CL (1) | CL2015001608A1 (pl) |
| CY (1) | CY1121895T1 (pl) |
| DK (1) | DK2931313T3 (pl) |
| EA (1) | EA034616B1 (pl) |
| ES (1) | ES2732861T3 (pl) |
| HK (1) | HK1215194A1 (pl) |
| HR (1) | HRP20191137T1 (pl) |
| HU (1) | HUE045668T2 (pl) |
| IL (3) | IL278295B2 (pl) |
| LT (1) | LT2931313T (pl) |
| MX (1) | MX357936B (pl) |
| MY (1) | MY187921A (pl) |
| NZ (1) | NZ708443A (pl) |
| PE (1) | PE20151524A1 (pl) |
| PH (1) | PH12015501296A1 (pl) |
| PL (1) | PL2931313T3 (pl) |
| PT (1) | PT2931313T (pl) |
| RS (1) | RS59057B1 (pl) |
| SI (1) | SI2931313T1 (pl) |
| TR (1) | TR201909584T4 (pl) |
| UA (1) | UA117466C2 (pl) |
| WO (1) | WO2014093203A1 (pl) |
| ZA (1) | ZA201504408B (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20200093927A1 (en) * | 2017-03-31 | 2020-03-26 | Meiji Seika Pharma Co., Ltd. | Aqueous formulation and in-syringe aqueous formulation, and antibody protein deaggregation agent and antibody protein deaggregation method |
| US20190269757A1 (en) * | 2018-03-05 | 2019-09-05 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
| BR112021009463A2 (pt) * | 2018-11-21 | 2021-08-10 | Regeneron Pharmaceuticals, Inc. | formulação de proteína de alta concentração |
| AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
| CA3127817A1 (en) * | 2019-02-20 | 2020-08-27 | Amgen Inc. | Methods of determining protein stability |
| AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
| TW202123965A (zh) * | 2019-09-09 | 2021-07-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| WO2021126435A1 (en) * | 2019-12-20 | 2021-06-24 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| EP4151233A1 (en) * | 2020-05-13 | 2023-03-22 | Innovent Biologics (Suzhou) Co., Ltd. | Preparation comprising anti-il-23p19 antibody, preparation method therefor and use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR022890A1 (es) | 1999-03-11 | 2002-09-04 | Schering Corp | Citoquinas mamiferas; reactivos relacionados y metodos |
| WO2001018051A2 (en) | 1999-09-09 | 2001-03-15 | Schering Corporation | Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
| DE60235013D1 (de) | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| CN1292655C (zh) * | 2001-11-08 | 2007-01-03 | 蛋白质设计实验室股份有限公司 | IgG抗体稳定的液态药物制剂 |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| KR20050110628A (ko) | 2003-02-10 | 2005-11-23 | 엘란 파마슈티칼스, 인크. | 면역글로불린 제제 및 이의 제조방법 |
| WO2004081190A2 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Uses of il-23 agonists and antagonists; related reagents |
| PL2335725T3 (pl) * | 2003-04-04 | 2017-04-28 | Genentech, Inc. | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
| BRPI0507794A (pt) | 2004-02-17 | 2007-07-17 | Schering Corp | métodos de modular a atividade de il-23, reagentes relacionados |
| EP1755673B1 (en) | 2004-04-12 | 2014-07-23 | MedImmune, LLC | Anti-il-9 antibody formulations and uses thereof |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| JP2009501006A (ja) | 2005-06-30 | 2009-01-15 | セントカー・インコーポレーテツド | 抗ｉｌ−２３抗体、組成物、方法および用途 |
| DK1937721T3 (da) | 2005-08-25 | 2010-10-18 | Lilly Co Eli | Anti-IL-23 antistoffer |
| DK1931710T3 (en) | 2005-08-31 | 2017-04-03 | Merck Sharp & Dohme | CONSTRUCTED ANTI-IL-23 ANTIBODIES |
| PL1971366T3 (pl) | 2005-12-29 | 2015-01-30 | Janssen Biotech Inc | Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie |
| CA2655372A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| JP5623743B2 (ja) | 2006-10-20 | 2014-11-12 | アムジエン・インコーポレーテツド | 安定なポリペプチド製剤 |
| PE20081610A1 (es) | 2007-01-09 | 2008-12-09 | Wyeth Corp | Formulaciones de anticuerpos anti-il-13 y usos de los mismos |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| CA2678863A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| NZ579158A (en) * | 2007-02-23 | 2012-01-12 | Schering Corp | Engineered anti-il-23p19 antibodies |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| EP2205276A4 (en) | 2007-09-28 | 2012-08-15 | Janssen Biotech Inc | ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| WO2009080541A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Antibody formulation |
| TW201008580A (en) * | 2008-06-03 | 2010-03-01 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| CN102202655B (zh) * | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
| MX2011003013A (es) * | 2008-09-19 | 2011-04-11 | Pfizer | Formulacion liquida estable de anticuerpos. |
| CN104398471A (zh) * | 2008-11-28 | 2015-03-11 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
| CN102686241A (zh) * | 2009-12-29 | 2012-09-19 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| PT2691112T (pt) * | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| SG10201609982PA (en) * | 2012-03-07 | 2017-01-27 | Cadila Healthcare Ltd | Pharmaceutical formulations of tnf-alpha anitbodies |
-
2013
- 2013-09-12 UA UAA201506824A patent/UA117466C2/uk unknown
- 2013-12-09 MX MX2015007213A patent/MX357936B/es active IP Right Grant
- 2013-12-09 CN CN201380065606.7A patent/CN104870016B/zh active Active
- 2013-12-09 NZ NZ708443A patent/NZ708443A/en unknown
- 2013-12-09 WO PCT/US2013/073825 patent/WO2014093203A1/en active Application Filing
- 2013-12-09 DK DK13863590.9T patent/DK2931313T3/da active
- 2013-12-09 EA EA201591133A patent/EA034616B1/ru unknown
- 2013-12-09 US US14/651,946 patent/US20150329632A1/en active Pending
- 2013-12-09 PE PE2015000925A patent/PE20151524A1/es active IP Right Grant
- 2013-12-09 ES ES13863590T patent/ES2732861T3/es active Active
- 2013-12-09 PT PT13863590T patent/PT2931313T/pt unknown
- 2013-12-09 CA CA2894869A patent/CA2894869C/en active Active
- 2013-12-09 JP JP2015547448A patent/JP6266012B2/ja active Active
- 2013-12-09 KR KR1020157018314A patent/KR102004585B1/ko active IP Right Grant
- 2013-12-09 SI SI201331504T patent/SI2931313T1/sl unknown
- 2013-12-09 IL IL278295A patent/IL278295B2/en unknown
- 2013-12-09 PL PL13863590T patent/PL2931313T3/pl unknown
- 2013-12-09 RS RS20190822A patent/RS59057B1/sr unknown
- 2013-12-09 BR BR112015013540-4A patent/BR112015013540B1/pt active IP Right Grant
- 2013-12-09 HU HUE13863590A patent/HUE045668T2/hu unknown
- 2013-12-09 MY MYPI2015701965A patent/MY187921A/en unknown
- 2013-12-09 LT LTEP13863590.9T patent/LT2931313T/lt unknown
- 2013-12-09 IL IL307581A patent/IL307581A/en unknown
- 2013-12-09 EP EP13863590.9A patent/EP2931313B1/en active Active
- 2013-12-09 AU AU2013359767A patent/AU2013359767B2/en active Active
- 2013-12-09 TR TR2019/09584T patent/TR201909584T4/tr unknown
-
2015
- 2015-06-02 IL IL239150A patent/IL239150B/en active IP Right Grant
- 2015-06-08 PH PH12015501296A patent/PH12015501296A1/en unknown
- 2015-06-10 CL CL2015001608A patent/CL2015001608A1/es unknown
- 2015-06-18 ZA ZA2015/04408A patent/ZA201504408B/en unknown
-
2016
- 2016-03-22 HK HK16103299.4A patent/HK1215194A1/zh unknown
-
2019
- 2019-06-21 HR HRP20191137TT patent/HRP20191137T1/hr unknown
- 2019-06-27 CY CY20191100675T patent/CY1121895T1/el unknown
-
2020
- 2020-12-08 US US17/114,754 patent/US20210188964A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201406414B (en) | Pharamaceuticals formulations of tnf-alpha antibodies | |
| HK1212701A1 (zh) | 恩雜魯胺製劑 | |
| HK1201296A1 (en) | Modified fc region of antibody fc | |
| HUE050276T2 (hu) | Anti-PCSK9 antitesteket tartalmazó stabil készítmények | |
| RS59221B1 (sr) | Formulacije antitela | |
| ZA201504408B (en) | Solution formulations of engineered anti-il-23p19 antibodies | |
| EP2917314A4 (en) | OLIGOMERATZUSAMMENSETZUNG | |
| HK1205524A1 (en) | Engineered conformationally-stabilized proteins | |
| IL236312A0 (en) | Preparation of 18f-flucyclobin | |
| EP2881113A4 (en) | NEW APPLICATION OF POGOSTONE | |
| EP2892529A4 (en) | USES OF (-) - PERHEXILINE | |
| EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
| TWM433525U (en) | Structure of calorifier |